EOCNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Galmed Pharmaceuticals Ltd.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Mar 31, 2026
$2.85−0.00 (-0.00%)
Close on Oct 19, 2026
- Market cap
- $2.71M
- P/E (TTM)
- 0.1
- Dividend yield
- –
Community
Notes and questions about Galmed Pharmaceuticals from other investors
No posts about EOCN yet
Discussion opens with sign-in. Posts will be able to point at any number on these pages, so everyone sees exactly which figure is being discussed.